Lactobacillus paracasei Impact on Myocardial Hypertrophy in Rats with Heart Failure
Subject Areas : Journal of Chemical Health RisksZohreh Hesari 1 , Khatereh Kafshdoozan 2 , Mahdi Barati 3 , Parviz Kokhaei 4 , Sina Andalib 5 , Fatemeh TalebiKiassari 6 , Mahboubeh Darban 7 , anna abdolshahi 8 , Bahador Bagheri 9
1 - Department of Pathobiology, School of Veterinary Medicine, Semnan University, Semnan, Iran
2 - Department of Pathobiology, School of Veterinary Medicine, Semnan University, Semnan, Iran
3 - Department of Immunology, Mashhad University of Medical Sciences, Mashhad, Iran
4 - Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran
5 - Department of Pharmacology, Zanjan University of Medical Sciences, Zanjan, Iran
6 - Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
7 - School of Medicine, Semnan University of Medical Sciences, Semnan, Iran
8 - Food Safety Research Center (salt), Semnan University of Medical Sciences, Semnan, Iran
9 - Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran
Keywords: Rat, Heart failure, Lactobacillus, Chemerin, Atrial Natriuretic Peptide,
Abstract :
Cardiac hypertrophy and cardiac dysfunction are important complications of heart failure. Cardiovascular, immunological, and hormonal players are involved in the pathogenesis of heart failure. Current evidence suggests that probiotics may have fruitful effects on the heart function. This was our aim. To this end, effects of oral administration of Lactobacillus paracasei subsp. paracasei 8700:2 on isoproterenol-induced heart failure were investigated. Forty male Wistar rats weighing 200 g were randomly assigned to five groups; the control group (saline-treated group), probiotic-treated group, heart failure group (isoproterenol-introduced group), pretreatment group (treating them by probiotic for 20 days then induced heart failure) and treatment group (following heart failure-induced, treating them by probiotic for 20 days). The groups were studied for 30 days. Serum levels of atrial natriuretic peptide (ANP) and chemerin were measured by ELISA. Finally, the hearts were removed for histopathological evaluation. Compared to the control group, isoproterenol caused cardiac hypertrophy and increased ANP (P < 0.05) and chemerin levels. Treatment with Lactobacillus paracasei significantly reduced the levels of ANP (P < 0.01) and decreased the pathological damages to the myocardium. It caused a small reduction in chemerin level, as well. Pretreatment with probiotics had no positive effects on cardiac hypertrophy and related parameters. Our findings indicate that treatment with Lactobacillus paracasei subsp. paracasei 8700:2 reduces cardiac hypertrophy in rats. In addition, this probiotic reduces the serum levels of chemerin and ANP.
1. Seta Y., Shan K., Bozkurt B., Oral H., Mann D.L., 1996. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 2(3), 243-249.
2. Takaki M., 2012. Cardiac mechanoenergetics for understanding isoproterenol-induced rat heart failure. Pathophysiology. 19 (3), 163-170.
3. Vasan R.S., Sullivan L.M., Roubenoff R., Dinarello C.A., Harris T., Benjamin E.J., Sawyer D.B., Levy D., Wilson P.W., D’Agostino R.B., 2003. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 107(11), 1486-1491.
4. Chander Hass Yadav M., Khanam R., 2014. Isoproterenol toxicity induced ECG alterations in wistar rats: role of histamine H3 receptor agonist imetit. IJPPS. 6(5), 23-33.
5. Noripour Sh., Molaei A., Bandari R., Emadi A., FarokhiFar S.M., Forozeshfard M., 2017. Comparison of the Results of Simultaneous Surfactant Administration and Nasal Continuous Positive Airway Pressure (INSURE) and Non-administration of Surfactant for the Treatment of Infants with Respiratory Distress Syndrome. Journal of Comprehensive Pediatrics. 8(1), e37462.
6. Wang I.K., Wu Y.Y., Yang Y.F., Ting I.W., Lin C.C., Yen T.H., Chen J.H., Wang C.H., Huang C.C., Lin H.C., 2015. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Beneficial Microbes. 6(4), 423-430.
7. Upaganlawar A., Gandhi H., Balaraman R., 2011. Isoproterenol induced myocardial infarction: Protective role of natural products. J Pharmacol Toxicol. 6(1), 1-17.
8. Gaggin H.K., Januzzi J.L., Jr., 2013. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 1832(12), 2442-2450.
9. Hasanzadeh H., Rezaie-Tavirani M., Seyyedi S., Emadi A., 2015. Proteomics Study of extremely low frequency electromagnetic field (50 Hz) on human neuroblastoma cells. Koomesh. 17(1), 233-238.
10. Nasr R., Hasanzadeh H., Khaleghian A., Moshtaghian A., Emadi A., Moshfegh S., 2018. Induction of apoptosis and inhibition of invasion in gastric cancer cells by titanium dioxide nanoparticles. Oman Medical Journal. 33(2), 111-117.
11. Ebel B., Lemetais G., Beney L., Cachon R., Sokol H., Langella P., Gervais P., 2014. Impact of probiotics on risk factors for cardiovascular diseases. A review. Crit Rev Food Sci Nutr. 54(2), 175-189.
12. Ljungh Å., Lan J., Yanagisawa N., 2002. Isolation, selection and characteristics of Lactobacillus paracasei subsp. paracasei F19. Microbial Ecology in Health and Disease. 14(1), 4-6.
13. Radulović Z., Petrović T., Nedović V., Dimitrijević S., Mirković N., Petrušić M., Paunović D., 2010. Characterization of autochthonous Lactobacillus paracasei strains on potential probiotic ability. Mljekarstvo: časopis za unaprjeđenje proizvodnje i prerade mlijeka. 60(2), 86-93.
14. Anker S. D., Von Haehling S., 2004. Inflammatory mediators in chronic heart failure: an overview. Heart, 90 (4), 464-470.
15. Phuong H.T. A., Yu L., Park B.M., Kim S.H., 2017. Comparative effects of angiotensin II and angiotensin-(4-8) on blood pressure and ANP secretion in rats. The Korean Journal of Physiology & Pharmacology. 21(6), 667-674.
16. Tian M., Yuan Y.C., Li J.Y., Gionfriddo M. R., Huang R.C., 2015. Tumor necrosis factor-α and its role as a mediator in myocardial infarction: a brief review. Chronic Diseases and Translational Medicine. 1(1), 18-26.
17. Kessler-Icekson G., Barhum Y., Schaper J., Schaper W., Kaganovsky E., Brand T., 2002. ANP expression in the hypertensive heart. Experimental & Clinical Cardiology. 7(2-3), 80-84.
18. Saito Y., 2010. Roles of atrial natriuretic peptide and its therapeutic use. Journal of Cardiology. 56(3), 262-270.
19. Tan R., Ahn Y.M., Kim H.Y., Lee Y.J., Cho K.W., Kang D.G., Lee H.S., 2018. Atrial secretion of ANP is suppressed in renovascular hypertension: shifting of ANP secretion from atria to the left ventricle. American Journal of Physiology-Heart and Circulatory Physiology. 315(3), H590-H601.
20. Braunwald E., 2008. Biomarkers in heart failure. New England Journal of Medicine. 358(20), 2148-2159.
21. Ernst M.C., Sinal C.J., 2010. Chemerin: at the crossroads of inflammation and obesity. Trends in Endocrinology & Metabolism. 21(11), 660-667.
22. Mattu H. S., Randeva H. S., 2013. Role of adipokines in cardiovascular. Journal of Endocrinology. 216, T17-T36.
23. Parolini S., Santoro A., Marcenaro E., Luini W., Massardi L., Facchetti F., Communi D., Parmentier M., Majorana A., Sironi M., 2007. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood. 109(9), 3625-3632.
24. Zabel B.A., Nakae S., Zúñiga L., Kim J.Y., Ohyama T., Alt C., Pan J., Suto H., Soler D., Allen S. J., 2008. Mast cell–expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. Journal of Experimental Medicine. 205(10), 2207-2220.
25. Feng W., Li W., 2010. The study of ISO induced heart failure rat model. Experimental and Molecular Pathology. 88 (2), 299-304.
26. Huang D., Ke J., Zhao A., Yang Z., Liang D., Pan J., Liu M., Chen J., 2014. Establishment and Evaluation of Isoproterenol Induced Chronic Heart Failure and Cardiac Remodeling Model in Rats: An Experimental Study. International Journal of Cardiovascular and Cerebrovascular Disease. 2(5), 45-50.
27. Gan X.T., Ettinger G., Huang C.X., Burton J.P., Haist J.V., Rajapurohitam V., Sidaway J.E., Martin G., Gloor G.B., Swann J.R., 2014. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circulation: Heart Failure. 7(3), 491-499.
28. Lin P.P., Hsieh Y.M., Kuo W.W., Lin Y.M., Yeh Y.L., Lin C.C., Tsai F.J., Tsai C.H., Huang C.Y., Tsai C.C., 2013. Probiotic-fermented purple sweet potato yogurt activates compensatory IGF‑IR/PI3K/Akt survival pathways and attenuates cardiac apoptosis in the hearts of spontaneously hypertensive rats. International Journal of Molecular Medicine. 32(6), 1319-1328.
29. Costanza A.C., Moscavitch S. D., Neto H.C.F., Mesquita E.T., 2015. Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial. International Journal of Cardiology. 179, 348-350.
30. Lutgendorff F., Nijmeijer R.M., Sandström P.A., Trulsson L.M., Magnusson K.E., Timmerman H.M., van Minnen L.P., Rijkers G.T., Gooszen H.G., Akkermans L.M., 2009. Probiotics prevent intestinal barrier dysfunction in acute pancreatitis in rats via induction of ileal mucosal glutathione biosynthesis. PLoS One. 4(2), e4512.
31. Yan F., Polk D. B., 2002. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. Journal of Biological Chemistry. 277 (52), 50959-50965.
32. Corthésy B., Gaskins H.. R., Mercenier A., 2007. Cross-talk between probiotic bacteria and the host immune system. The Journal of Nutrition. 137(3), 781S-790S.
33. Bagheri B., Sohrabi B., Movassaghpur A., Mashayekhi S., Garjani A., Shokri M., Noori M., Garjani A., 2012. Monocyte expression of toll-like receptor-4 in patients with stable angina undergoing percutanoeus coronary intervention. Iranian Journal of Immunology. 9(3), 149-158.
34. Sadeghzadeh J., Vakili A., Sameni H.R., Shadnoush M., Bandegi A.R., Khorasani M.Z., 2017. The effect of oral consumption of probiotics in prevention of heart injury in a rat myocardial infarction model: A Histopathological, Hemodynamic and Biochemical Evaluation. Iranian Biomedical Journal. 21(3), 174-181.